Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer

Liu,Yongping; Ling,Yang; Qi,Qiufeng; Tang,Yexin; Xu,Jianzhong; Zhou,Tong; Sheng,Guifeng; Yang,Quanliang; Pan,Yaodong

doi:10.3892/etm.2011.338

November-December 2011 Volume 2 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2011 Volume 2 Issue 6

Full Size Image

Article

Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer

Authors:
- Yongping Liu
- Yang Ling
- Qiufeng Qi
- Yexin Tang
- Jianzhong Xu
- Tong Zhou
- Guifeng Sheng
- Quanliang Yang
- Yaodong Pan
View Affiliations / Copyright

Affiliations: Clinical Oncology Laboratory, Changzhou Tumor Hospital Affiliated with Suzhou University, Changzhou 213002, P.R. China, Department of Oncology, Changzhou Tumor Hospital Affiliated with Suzhou University, Changzhou 213002, P.R. China, Department of Gastroenterological Surgery, Changzhou Tumor Hospital Affiliated with Suzhou University, Changzhou 213002, P.R. China
Pages: 1177-1181
|
Published online on: August 17, 2011

https://doi.org/10.3892/etm.2011.338
Expand metrics +

Abstract

Serum thymidine kinase 1 (STK1) is a reliable proliferation marker in most solid tumors, including gastric cancer. The aim of this study was to evaluate whether STK1 levels are related to the tumor response to chemotherapy and survival in advanced gastric cancer. The results showed that the average STK1 level in patients with gastric cancer (5.57±3.07 pM) was significantly higher than that in the healthy controls (1.12±0.57) (P<0.001). Among the 84 patients, the average STK1 level (6.02±3.12) in the 56 patients who did not undergo surgery was higher than the level (4.68±2.78) in the 28 patients who received surgery (P=0.049). The STK1 value correlated with clinical stage, ECOG PS and serum CEA levels (P<0.001, P=0.001 and P=0.004, respectively), but not with age and gender. The average STK1 levels after 1, 2 and 4 cycles of chemotherapy did not significantly decrease in the total patients, when compared to the levels prior to chemotherapy. Yet, after 2 cycles of chemotherapy, the average level of STK1 was significantly decreased in patients who achieved an objective response (OR) (CR, PR or no recurrence). Particularly after 1 cycle of chemotherapy, the average level of STK1 in patients who achieved OR started to decline, while in most of the patients with disease progression or recurrence, the STK1 level started to increase. In patients receiving palliative chemotherapy or receiving adjuvant chemotherapy, a significant difference in the median PFS (median PFS, not defined vs. 4 months, P<0.001) or RFS (median RFS, not defined vs. 5 months, P<0.001) was noted between patients with decreased STK1 levels and patients with increased STK1 levels during the first 2 months of chemotherapy. The log-rank test showed that patients with decreased STK1 levels had a trend of a longer OS in the palliative chemotherapy group. Our results suggest that serum TK1 levels correlate with clinical stage, ECOG PS and serum CEA levels in patients with gastric cancer, and changes in STK1 levels during the first 2 months of chemotherapy may be more important for evaluating chemotherapy response, predicting PFS and RFS than baseline values of STK1 in patients with advanced gastric cancer.

View Figures

View References

1	Leung WK, Wu MS, Kakugawa Y, et al: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
3	Macdonald JS: Treatment of localized gastric cancer. Semin Oncol. 31:566–573. 2004. View Article : Google Scholar : PubMed/NCBI
4	Wagner AD, Unverzagt S, Grothe W, et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. CD004064:2010. View Article : Google Scholar
5	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
6	Xu XH, Zhang YM, Shu XH, et al: Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep. 1:705–711. 2008.PubMed/NCBI
7	Paesmans M, Sculier JP, Libert P, et al: Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer. 33:2326–2332. 1997.PubMed/NCBI
8	Ke PY and Chang ZF: Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol. 24:514–526. 2004. View Article : Google Scholar : PubMed/NCBI
9	He Q, Mao Y, Wu J, et al: Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol. 25:945–953. 2004.PubMed/NCBI
10	O'Neill KL, Buckwalter MR and Murray BK: Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Diagn. 1:428–433. 2001.PubMed/NCBI
11	He Q, Zou L, Zhang PA, Lui JX, Skog S and Fornander T: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int J Biol Markers. 15:139–146. 2000.PubMed/NCBI
12	Zou L, Zhang PG, Zou S, Li Y and He Q: The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers. 17:135–140. 2002.PubMed/NCBI
13	Chen Y, Ying M, Hu M, et al: Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol. 15:359–368. 2010. View Article : Google Scholar : PubMed/NCBI
14	He Q, Fornander T, Johansson H, et al: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 26:4753–4759. 2006.PubMed/NCBI
15	Kallander CF, Simonsson B, Hagberg H and Gronowitz JS: Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer. 54:2450–2455. 1984. View Article : Google Scholar : PubMed/NCBI
16	Hallek M, Langenmayer I, Nerl C, et al: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 93:1732–1737. 1999.
17	Hallek M, Wanders L, Ostwald M, et al: Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 22:439–447. 1996. View Article : Google Scholar : PubMed/NCBI
18	Magnac C, Porcher R, Davi F, et al: Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 17:133–137. 2003. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles